JP Morgan Chase’s Ultragenyx Pharmaceutical RARE Stock Holding History

JP Morgan Chase’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-89,600	Closed	-$2.06M	–	7822
2025 Q4	$2.06M	Buy	89,600 +67,700	+309%	+$2.23M	﹤0.01%	4047
2025 Q3	$659K	Sell	21,900 -95,600	-81%	-$2.87M	﹤0.01%	4864
2025 Q2	$4.27M	Buy	117,500 +66,500	+130%	+$2.4M	﹤0.01%	3299
2025 Q1	$1.85M	Buy	51,000 +21,000	+70%	+$874K	﹤0.01%	3941
2024 Q4	$1.26M	Buy	+30,000	New	+$1.49M	﹤0.01%	4459
2024 Q3	–	Sell	-35,000	Closed	-$1.44M	–	7626
2024 Q2	$1.44M	Hold	35,000	–	–	﹤0.01%	4018
2024 Q1	$1.63M	Buy	+35,000	New	+$1.65M	﹤0.01%	4000
2019 Q2	–	Sell	-95,000	Closed	-$6.59M	–	5961
2019 Q1	$6.59M	Buy	+95,000	New	+$5.43M	﹤0.01%	2363
2018 Q3	–	Sell	-30,000	Closed	-$2.31M	–	5788
2018 Q2	$2.31M	Buy	+30,000	New	+$1.94M	﹤0.01%	3310

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase's RARE Position: Q1 2026 in Review

JP Morgan Chase reduced its Ultragenyx Pharmaceutical (RARE) stake by 94% in Q1 2026, selling an estimated $84M and leaving 245,928 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

JP Morgan Chase first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $121M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

JP Morgan Chase held 245,928 shares of Ultragenyx Pharmaceutical worth $4.75M as of Q1 2026.
JP Morgan Chase sold 3,728,102 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $84M.
Ultragenyx Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3358 holding.
JP Morgan Chase first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
JP Morgan Chase's Ultragenyx Pharmaceutical position peaked at $121M in Q3 2025.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.